LIVE Programme
CET Time
SESSION II – Biology of MDS – Genetic Abnormalities
Chairs: Maria (Ken) Figueroa (Miami) & Mikkael Sekeres (Miami)
15:20-15:25 Introduction Maria (Ken) Figueroa (Miami)
Mikkael Sekeres (Miami)
`
15:25-15:40 Review of currently available pre-clinical models Daniel Nowak (Mannheim)
(including zebra fish) of MDS
15:40-15:55 Multiple acquired clonal steps to MDS, Olivier Kosmider (Paris)
molecular architecture and its progression to AML
15:55-16:10 Druggable molecular targets in MDS Torsten Haferlach (Munich)
and elderly AML (IDH, TP53…)
16:10-16:25 Epigenetic abnormalities in MDS and their relationship with Maria (Ken) Figueroa (Miami)
somatic mutations
16:25-16:40 Spliceosome mutations and their consequences in MDS? Austin Kulasekararaj (London)
SHORT COMMUNICATION:
16:40-16:50 Impact of Somatic Mutations in Myelodysplastic Patients with Elena Crisà (Novara)
Isolated Partial or Total Loss of Chromosome 7
16:50-17:20 Panel discussion
17:25-18:25 SATELLITE SYMPOSIUM:
Title: Ineffective Erythropoiesis: Understanding the biology, optimising clinical practice
Chair: Uwe Platzbecker (Leipzig)
Speakers: Michaela Fontenay (Paris) & Paresh Vyas (Oxford)
MDS Satellite Symposium organized and funded by Celgene | A Bristol Myers Squibb Company
SESSION III – Biology of MDS: Stem Cells and the Microenvironment
Chairs: Hind Medyouf (Frankfurt) & Uwe Platzbecker (Leipzig)
18:30-18:35 Introduction Hind Medyouf (Frankfurt)
Uwe Platzbecker (Leipzig)
18:35-18:50 The niche in MDS: Inflammation driving evolution Marc H.G.P. Raaijmakers (Rotterdam)
18:50-19:05 Bone biology and the osteo-hematopoietic niche Ulrike Baschant (Dresden)
19:05-19:20 Hematopoietic stem cells in MDS: The real targets? Ulrich Steidl (New York)
19:20-19:35 Mesenchymal stem cells in MDS: The better targets? Hind Medyouf (Frankfurt)
2
SCIENTIFIC PROGRAMME
SESSION I
ETIOLOGY OF MDS
SESSION II
BIOLOGY OF MDS –
GENETIC ABNORMALITIES
SESSION III
BIOLOGY OF MDS:
STEM CELLS AND THE
MICROENVIRONMENT
SESSION IV
DIAGNOSTIC WORKUP
AND PROGNOSTIC
FACTORS IN MDS
SESSION V
SPECIFIC SUBTYPES
OF MDS, BASED ON
MORPHOLOGY AND
MOLECULAR BIOLOGY
SESSION VI
TREATMENT OF MDS
SESSION VII
CURRENT PROGRESS IN
THE TREATMENT OF MDS
SESSION VIII
FUTURE TREATMENTS
AND TREATMENT
STRATEGIES IN MDS
SESSION IX
LATE-BREAKING TALKS
SELECTED ABSTRACTS
FOR AN ORAL
PRESENTATION
SELECTED ABSTRACTS
AS E-POSTERS
DISCLOSURES